BlackRock’s Kiniksa Pharmaceuticals KNSA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $175M | Buy |
2,739,615
+2,252,878
| +463% | +$117M | ﹤0.01% | 1879 |
|
|
2026
Q1 | $23.4M | Buy |
486,737
+40,134
| +9% | +$1.78M | ﹤0.01% | 2977 |
|
|
2025
Q4 | $18.4M | Sell |
446,603
-11,044
| -2% | -$443K | ﹤0.01% | 3142 |
|
|
2025
Q3 | $17.8M | Sell |
457,647
-245,233
| -35% | -$7.97M | ﹤0.01% | 3152 |
|
|
2025
Q2 | $19.4M | Sell |
702,880
-2,729,819
| -80% | -$69.5M | ﹤0.01% | 3046 |
|
|
2025
Q1 | $76.2M | Sell |
3,432,699
-139,164
| -4% | -$2.86M | ﹤0.01% | 2157 |
|
|
2024
Q4 | $70.7M | Sell |
3,571,863
-245,393
| -6% | -$5.6M | ﹤0.01% | 2259 |
|
|
2024
Q3 | $95.4M | Sell |
3,817,256
-773,880
| -17% | -$18.9M | ﹤0.01% | 2114 |
|
|
2024
Q2 | $85.7M | Buy |
4,591,136
+397,229
| +9% | +$7.44M | ﹤0.01% | 2112 |
|
|
2024
Q1 | $82.7M | Buy |
4,193,907
+1,013,319
| +32% | +$19.8M | ﹤0.01% | 2169 |
|
|
2023
Q4 | $55.8M | Buy |
3,180,588
+62,280
| +2% | +$1.02M | ﹤0.01% | 2413 |
|
|
2023
Q3 | $54.2M | Sell |
3,118,308
-42,116
| -1% | -$710K | ﹤0.01% | 2353 |
|
|
2023
Q2 | $44.5M | Sell |
3,160,424
-225,736
| -7% | -$3.02M | ﹤0.01% | 2550 |
|
|
2023
Q1 | $36.4M | Sell |
3,386,160
-195,519
| -5% | -$2.58M | ﹤0.01% | 2655 |
|
|
2022
Q4 | $53.7M | Sell |
3,581,679
-46,781
| -1% | -$681K | ﹤0.01% | 2416 |
|
|
2022
Q3 | $46.6M | Buy |
3,628,460
+93,103
| +3% | +$1.06M | ﹤0.01% | 2493 |
|
|
2022
Q2 | $34.3M | Buy |
3,535,357
+41,032
| +1% | +$383K | ﹤0.01% | 2753 |
|
|
2022
Q1 | $34.7M | Buy |
3,494,325
+10,473
| +0.3% | +$111K | ﹤0.01% | 2807 |
|
|
2021
Q4 | $41M | Buy |
3,483,852
+363,530
| +12% | +$4.47M | ﹤0.01% | 2788 |
|
|
2021
Q3 | $35.5M | Buy |
3,120,322
+621,032
| +25% | +$8.09M | ﹤0.01% | 2888 |
|
|
2021
Q2 | $34.8M | Buy |
2,499,290
+248,679
| +11% | +$3.78M | ﹤0.01% | 2941 |
|
|
2021
Q1 | $41.7M | Buy |
2,250,611
+61,381
| +3% | +$1.26M | ﹤0.01% | 2742 |
|
|
2020
Q4 | $38.7M | Buy |
2,189,230
+359,711
| +20% | +$6.32M | ﹤0.01% | 2625 |
|
|
2020
Q3 | $28M | Buy |
1,829,519
+632,699
| +53% | +$11.9M | ﹤0.01% | 2671 |
|
|
2020
Q2 | $30.5M | Buy |
1,196,820
+263,807
| +28% | +$5.51M | ﹤0.01% | 2566 |
|
|
2020
Q1 | $14.4M | Sell |
933,013
-15,444
| -2% | -$242K | ﹤0.01% | 2786 |
|
|
2019
Q4 | $10.5M | Sell |
948,457
-169,462
| -15% | -$1.47M | ﹤0.01% | 3225 |
|
|
2019
Q3 | $9.51M | Buy |
1,117,919
+10,828
| +1% | +$120K | ﹤0.01% | 3234 |
|
|
2019
Q2 | $15M | Buy |
1,107,091
+139,072
| +14% | +$2.16M | ﹤0.01% | 3011 |
|
|
2019
Q1 | $17.5M | Buy |
968,019
+322,908
| +50% | +$6.24M | ﹤0.01% | 2815 |
|
|
2018
Q4 | $18.1M | Buy |
645,111
+194,538
| +43% | +$4.06M | ﹤0.01% | 2773 |
|
|
2018
Q3 | $11.5M | Buy |
450,573
+440,573
| +4,406% | +$8.57M | ﹤0.01% | 3170 |
|
|
2018
Q2 | $173K | Buy |
+10,000
| New | +$181K | ﹤0.01% | 4337 |
|
Other funds holding KNSA
RCMNY
BBA
TCM
SSC
BlackRock's KNSA Position: Q2 2026 in Review
BlackRock increased its Kiniksa Pharmaceuticals (KNSA) stake by 463% in Q2 2026, buying an estimated $117M and bringing the position to 2,739,615 shares worth $175M. The position accounts for ﹤0.01% of the portfolio, ranked #1879.
BlackRock first reported a position in KNSA in Q2 2018 and has held it in 33 quarters since. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.
- BlackRock held 2,739,615 shares of Kiniksa Pharmaceuticals worth $175M as of Q2 2026.
- BlackRock bought 2,252,878 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $117M.
- Kiniksa Pharmaceuticals made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #1879 holding.
- BlackRock first reported a position in Kiniksa Pharmaceuticals in Q2 2018 and has held it in 33 quarters since.
- 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.
Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.